Bicara Therapeutics (BCAX) Competitors $11.64 +0.23 (+2.02%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$11.64 +0.00 (+0.04%) As of 08/15/2025 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BCAX vs. BLTE, RXRX, BHC, OCUL, AGIO, DNLI, IDYA, TARS, IRON, and HRMYShould you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include Belite Bio (BLTE), Recursion Pharmaceuticals (RXRX), Bausch Health Cos (BHC), Ocular Therapeutix (OCUL), Agios Pharmaceuticals (AGIO), Denali Therapeutics (DNLI), IDEAYA Biosciences (IDYA), Tarsus Pharmaceuticals (TARS), Disc Medicine (IRON), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Bicara Therapeutics vs. Its Competitors Belite Bio Recursion Pharmaceuticals Bausch Health Cos Ocular Therapeutix Agios Pharmaceuticals Denali Therapeutics IDEAYA Biosciences Tarsus Pharmaceuticals Disc Medicine Harmony Biosciences Bicara Therapeutics (NASDAQ:BCAX) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations. Do institutionals and insiders hold more shares of BCAX or BLTE? 0.5% of Belite Bio shares are owned by institutional investors. 15.5% of Bicara Therapeutics shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has better valuation & earnings, BCAX or BLTE? Belite Bio is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/A-$68M-$3.17-3.67Belite BioN/AN/A-$36.14M-$1.55-42.99 Does the media prefer BCAX or BLTE? In the previous week, Belite Bio had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 18 mentions for Belite Bio and 17 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.45 beat Belite Bio's score of -0.14 indicating that Bicara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Belite Bio 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is BCAX or BLTE more profitable? Bicara Therapeutics' return on equity of -21.67% beat Belite Bio's return on equity.Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A -21.67% -20.89% Belite Bio N/A -34.90%-33.56% Do analysts prefer BCAX or BLTE? Bicara Therapeutics currently has a consensus price target of $31.86, suggesting a potential upside of 173.70%. Belite Bio has a consensus price target of $96.67, suggesting a potential upside of 45.08%. Given Bicara Therapeutics' higher possible upside, research analysts plainly believe Bicara Therapeutics is more favorable than Belite Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Belite Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryBicara Therapeutics beats Belite Bio on 8 of the 12 factors compared between the two stocks. Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition Export to ExcelMetricBicara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$622.56M$3.10B$5.67B$9.82BDividend YieldN/A2.23%3.79%4.08%P/E Ratio-3.6720.3830.5825.12Price / SalesN/A368.28464.36116.51Price / CashN/A42.3037.4059.05Price / Book1.468.659.096.18Net Income-$68M-$54.65M$3.25B$264.89M7 Day Performance14.12%6.58%7.42%4.22%1 Month Performance7.88%7.54%5.50%2.02%1 Year PerformanceN/A13.73%30.67%24.22% Bicara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara Therapeutics1.9688 of 5 stars$11.64+2.0%$31.86+173.7%N/A$622.56MN/A-3.6732News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionBLTEBelite Bio2.5524 of 5 stars$69.50-0.5%$96.67+39.1%+33.5%$2.22BN/A-51.1010News CoverageEarnings ReportAnalyst RevisionRXRXRecursion Pharmaceuticals1.4595 of 5 stars$5.29-1.3%$7.00+32.3%-13.8%$2.18B$58.84M-2.97400BHCBausch Health Cos3.3854 of 5 stars$6.68+16.1%$9.00+34.8%+45.3%$2.13B$9.63B25.6820,700News CoveragePositive NewsInsider TradeOptions VolumeGap UpHigh Trading VolumeOCULOcular Therapeutix4.0768 of 5 stars$12.56+2.9%$17.20+36.9%+50.8%$2.12B$63.72M-9.81230AGIOAgios Pharmaceuticals4.377 of 5 stars$35.10-1.8%$56.33+60.5%-17.6%$2.08B$36.50M3.19390Insider TradeDNLIDenali Therapeutics4.1596 of 5 stars$13.91-0.3%$33.85+143.3%-37.9%$2.03B$330.53M-5.21430Trending NewsEarnings ReportAnalyst RevisionIDYAIDEAYA Biosciences4.4456 of 5 stars$22.84-1.1%$48.09+110.6%-36.2%$2.02B$7M-6.0380TARSTarsus Pharmaceuticals1.7934 of 5 stars$50.07+4.6%$66.67+33.1%+101.1%$2.02B$182.95M-21.4950News CoverageInsider TradeIRONDisc Medicine3.3143 of 5 stars$58.59+1.0%$95.73+63.4%+23.9%$2.01BN/A-13.1130Insider TradeHRMYHarmony Biosciences4.5038 of 5 stars$34.80+1.8%$51.00+46.6%+4.6%$1.97B$714.73M11.23200 Related Companies and Tools Related Companies BLTE Competitors RXRX Competitors BHC Competitors OCUL Competitors AGIO Competitors DNLI Competitors IDYA Competitors TARS Competitors IRON Competitors HRMY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAX) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access